6533b7d3fe1ef96bd1261564
RESEARCH PRODUCT
Cardiac effects of isoliquiritigenin
Jörg W. WegenerHermann Nawrathsubject
Malemedicine.medical_specialtyPatch-Clamp TechniquesFura-2In Vitro TechniquesMembrane PotentialsRats Sprague-Dawleychemistry.chemical_compoundChalconeChalconesAldehyde ReductaseInternal medicineIsoprenalinemedicineAnimalsDrug InteractionsEnzyme InhibitorsCyclic GMPPharmacologyPlants MedicinalForskolinMyocardiumPhosphodiesteraseHeartCyclic AMP-Dependent Protein KinasesMyocardial ContractionRatsElectrophysiologyEndocrinologychemistryGuanylate CyclaseMilrinoneCalciumFemalemedicine.symptomSoluble guanylyl cyclaseIsoliquiritigeninMuscle contractionmedicine.drugdescription
The effects of isoliquiritigenin on force of contraction (Fc), L-type Ca2+ current (I(Ca)) and intracellular Ca2+ concentration ([Ca2+]i) were investigated in rat ventricular heart muscle. Isoliquiritigenin increased Fc and I(Ca) and, after longer exposure times, resting tension and [Ca2+]i. The effect of isoliquiritigenin (100 microM) on I(Ca) was diminished by Rp-cAMPS (30 microM). 1H-[1,2,4]oxa- diazolo[4,3-a]quinoxalin-1-one (50 microM) did not influence the effects of isoliquiritigenin on Fc and I(Ca). The positive inotropic effects of isoprenaline and forskolin, but not of 3-isobutyl-1-methylxanthine, were potentiated by isoliquiritigenin (100 microM). In the presence of milrinone (10 microM), no further effects of isoliquiritigenin (100 microM) on Fc and I(Ca) were observed. It is suggested that the increase in Fc and I(Ca) by isoliquiritigenin is due to an accumulation of cyclic AMP. These effects are probably unrelated to an effect of the drug on soluble guanylyl cyclase, as reported for smooth muscle, but rather due to a direct inhibition of phosphodiesterase III activity.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1997-05-12 | European Journal of Pharmacology |